Clinical Trial

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

Study acronym: PROSPECT-1
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.
Protocol Amendment History 28 amendments
This ClinicalTrials.gov record has been amended 28 times since 2023-05-31; most recent amendment 2026-07-13.
Status change: Not Yet Recruiting → Recruiting 2023-06-20
Trial Details
NCT Number NCT05897320
Lead Sponsor H. Lundbeck A/S
Conditions Episodic Migraine
Enrollment 315 participants
Start Date 2023-06-08
Primary Completion 2027-07-06 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-14